Manganese produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this Parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism. Animal experiments have given the opportunity to examine the consequences of manganese overexposure under controlled conditions.
Manganese(II) oxide mostly for demonstration purposes, is the oxalate method, which also applicable to the synthesis of ferrous oxide and stannous oxide. Upon heating in an oxygen-free atmosphere (usually CO), manganese(II) oxalate decomposes into MnO: Together with manganese sulfate, MnO is a component of fertilizers and food additives. Many thousands of tons are consumed annually for this purpose. Other uses include: a catalyst in the manufacture of allyl alcohol, ceramics, paints, colored glass, bleaching tallow and textile printing. Manganese(II) oxide Manganese(II) oxide is an inorganic compound with chemical formula MnO. It forms green crystals. The compound is produced on a large scale